Chemistry:Zibotentan
From HandWiki
| |
| Names | |
|---|---|
| Preferred IUPAC name
N-(3-Methoxy-5-methylpyrazin-2-yl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]pyridine-3-sulfonamide | |
| Other names
ZD4054
| |
| Identifiers | |
3D model (JSmol)
|
|
| ChemSpider | |
PubChem CID
|
|
| UNII | |
| |
| |
| Properties | |
| C19H16N6O4S | |
| Molar mass | 424.44 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
 verify (what is   ?)
| |
| Infobox references | |
Tracking categories (test):
Zibotentan (INN; development code ZD4054) is an experimental anti-cancer drug candidate in development by AstraZeneca.[1] It is an endothelin receptor antagonist.[2]
Zibotentan was granted fast track status for the treatment of prostate cancer by the FDA.
It failed a phase III clinical trial for prostate cancer,[3] but other trials are planned.[4] Tolerability of zibotentan plus docetaxel has been evaluated.[5]
Zibotentan has also been studied in clinical trials for treatment of breast cancer, colorectal cancer, non-small cell lung cancer, ovarian cancer, scleroderma-related renal disease,[6] bone metastasis, and heart failure.[7]
References
- ↑ James and Growcott (2009). "Drugs of the Future". http://journals.prous.com/journals/servlet/xmlxsl/pk_journals.xml_summary_pr?p_JournalId=2&p_RefId=1400202&p_IsPs=N.
- ↑ "Pharmacokinetics and tolerability of zibotentan (ZD4054) in subjects with hepatic or renal impairment: two open-label comparative studies". BMC Clin Pharmacol 11: 3. 2011. doi:10.1186/1472-6904-11-3. PMID 21414193.
- ↑ "AZ's zibotentan flunks late-stage prostate cancer trial - FierceBiotech". http://www.fiercebiotech.com/story/azs-zibotentan-flunks-late-stage-prostate-cancer-trial/2010-09-27.
- ↑ "Pfizer, AstraZeneca, and Actelion Separately Report Phase III Trial Failures - GEN". 28 September 2010. http://www.genengnews.com/gen-news-highlights/pfizer-astrazeneca-and-actelion-separately-report-phase-iii-trial-failures/81243985/.
- ↑ "Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer". Prostate 71 (12): 1264–75. September 2011. doi:10.1002/pros.21342. PMID 21271613.
- ↑ "A Phase II, Single Centre, Randomised, Placebo-controlled, 3-part Trial to Assess the Safety, Tolerability and Efficacy of Zibotentan in Patients With Renal Disease Secondary to Scleroderma - AdisInsight". http://adisinsight.springer.com/trials/700241643.
- ↑ "Zibotentan - AdisInsight". http://adisinsight.springer.com/drugs/800009560.
External links
 |  |
